

RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.



PART I (Rs. in lakhs)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2013

PARTICULARS	3 months ended	3 months ended	3 months ended	9 months ended	9 months ended	Year ended
	31.12.2013	30.9.2013	31.12.2012	31.12.2013	31.12.2012	31.3.2013
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income from Operations						
(a) Net Sales/Income from Operations (Net of Excise Duty)	5,479	6,055	4,809	17,824	15,987	21,621
(b) Other Operating Income	201	106	78	435	312	543
Total Income from Operations (Net)	5,680	6,161	4,887	18,259	16,299	22,164
2. Expenses						
(a) Cost of Materials Consumed	1,514	1,815	1,359	5,239	4,267	5,479
(b) Purchases of Stock-in-Trade	507	617	411	1,573	1,455	1,880
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(85)	(542)	41	(977)	(157)	285
(d) Employee Benefits Expense	1,510	1,740	1,391	4,722	4,169	5,520
(e) Depreciation and Amortisation Expense	271	263	257	788	734	987
(f) Provision for Doubtful Debts and Advances (Net) [Refer Note 4]	681	16	-	717	7	34
(g) Other Expenses	1,841	2,141	1,929	6,057	5,697	7,359
Total Expenses	6,239	6,050	5,388	18,119	16,172	21,544
3. (Loss)/Profit from Operations before Other Income, Finance Costs and Exceptional Items	(559)	111	(501)	140	127	620
4. Other Income	49	85	62	218	112	178
5. (Loss)/Profit from Ordinary Activities before Finance Costs and Exceptional Items	(510)	196	(439)	358	239	798
6. Finance Costs	34	26	196	221	538	744
7. (Loss)/Profit from Ordinary Activities after Finance Costs but before Exceptional Items	(544)	170	(635)	137	(299)	54
8. Exceptional Items	-	-	-	6,426	-	-
9. (Loss)/Profit from Ordinary Activities before Tax	(544)	170	(635)	6,563	(299)	54
10. Tax (Credit)/Expense (including Deferred Tax)	(242)	(54)	(26)	1,172	-	(387)
11. Net (Loss)/Profit for the period	(302)	224	(609)	5,391	(299)	441
12. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323	1,323
13. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)						6,300
14. (Loss)/Earnings per Share (of Rs. 8 each) (not annualised):						
(a) Basic	(1.83)	1.36	(3.68)	32.60	(1.81)	2.67
(b) Diluted	(1.83)	1.36	(3.68)	32.60	(1.81)	2.67

PART II
SELECT INFORMATION FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2013

PARTICULARS	3 months ended	3 months ended	3 months ended	9 months ended	9 months ended	Year ended
	31.12.2013	30.9.2013	31.12.2012	31.12.2013	31.12.2012	31.3.2013
A PARTICULARS OF SHAREHOLDING						
1. Public Shareholding						
- Number of Shares	7,196,344	7,196,344	7,196,344	7,196,344	7,196,344	7,196,344
- Percentage of Shareholding	43.52	43.52	43.52	43.52	43.52	43.52
2. Promoters and Promoter Group Shareholding						
(a) Pledged/Encumbered						
- Number of Shares	-	-	-	-	-	-
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-	-	-
- Percentage of Shares (as a % of the total Share Capital of the company)	-	-	-	-	-	-
(b) Non-Encumbered						
- Number of Shares	9,338,897	9,338,897	9,338,897	9,338,897	9,338,897	9,338,897
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total Share Capital of the company)	56.48	56.48	56.48	56.48	56.48	56.48

PARTICULARS	3 months ended 31.12.2013
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	6
Disposed of during the quarter	6
Remaining unsolved at the end of the quarter	-

- Notes:**
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 7th February, 2014.
 - The results for the quarter ended 31st December, 2013 have been subjected to limited review by the statutory auditors of the company.
 - The company is exclusively engaged in the pharmaceuticals segment.
 - Provision for Doubtful Debts and Advances (Net) for the quarter and nine months ended 31st December, 2013 includes an amount of Rs. 674 lakhs towards receivable from certain parties to whom pharmaceutical goods were supplied as per contracts and for which these parties have reneged on the contractual payment terms. The company has initiated legal action against these parties. Without prejudice to the position that Rs. 674 lakhs is recoverable, the company has made provision for the same.
 - Exceptional Items for the nine months ended 31st December, 2013 comprise of profit of Rs. 6,184 lakhs on sale of a portion of leasehold land and building thereon and the company's share of interest income of Rs. 242 lakhs earned on the sale consideration deposited by the buyer in an escrow account, jointly held in the name of the company and the buyer, till the execution of the sale deed. The amount of sale consideration and the company's share of interest income lying in the escrow account has been transferred to the company on 6th June, 2013, the date of execution of the sale deed.
 - Figures for the prior periods have been regrouped where necessary.

For RPG Life Sciences Limited
Ajit Singh Chouhan
Managing Director
Mumbai, 7th February, 2014